Retatrutide 5mg

Tier

Packs	Discount (%)	For Each
1 - 5	—	$100.00
6 - 10	10 %	$90.00
11 - 20	19 %	$81.00
21+	27 %	$73.00

Product description

What is Retatrutide 5mg?

Retatrutide (5 mg) is a synthetically manufactured 39-amino acid peptide engineered as a triple receptor agonist with selective activity across three distinct metabolic hormone pathways. It has been extensively studied in research environments for its ability to simultaneously engage:

GIP (glucose-dependent insulinotropic polypeptide) receptor
GLP-1 (glucagon-like peptide-1) receptor
Glucagon receptor

This unimolecular, multi-target design represents a significant advancement in laboratory investigations of coordinated metabolic receptor signaling. Structurally, retatrutide consists of 39 amino acids with a molecular weight of 4731.33 g/mol and a molecular formula of C221H342N46O68. The sequence incorporates specialized amino acid modifications including:

Aib (α-aminoisobutyric acid) at positions 2 and 20
α-methyl-leucine (α-Me-Leu) at position 13

These modifications enhance enzymatic stability and receptor selectivity in experimental systems. The peptide backbone is conjugated to a C20 fatty diacid moiety via a linker at position 17, extending biological activity duration in research models. Research-grade material is supplied as a lyophilized powder with ≥98% purity, verified through HPLC and mass spectrometry.

Product Specifications

Product Name: Retatrutide
Synonyms: Retatrutide acetate, LY3437943
CAS Number: 2381089-83-2
Chemical Formula: C221H342N46O68
Subscript Format: C₂₂₁H₃₄₂N₄₆O₆₈
Molecular Weight: 4731.33 g/mol
Sequence: Tyr-{Aib}-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-{α-Me-Leu}-Leu-Asp-Lys-{diacid-C20-gamma-Glu-(AEEA)-Lys}-Ala-Gln-{Aib}-Ala-Phe-Ile-Glu-Tyr-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH₂ (Sodium salt)
Structure Type: Long-chain tri-agonist peptide with C20 fatty diacid conjugation

What are the key features of Retatrutide 5mg?

Retatrutide 5mg is characterized by its novel triple-agonist architecture and enhanced stability profile compared to single-target peptides. The compound is supplied as a lyophilized (freeze-dried) powder in sealed vials, allowing researchers to prepare precise concentrations for controlled experimental work using sterile reconstitution techniques. The specialized amino acid modifications and C20 lipid conjugation provide superior enzymatic resistance and extended activity duration in laboratory systems. Key features include:

≥98% purityconfirmed by HPLC and mass spectrometry analysis
39-amino acid sequencewith three specialized amino acid modifications (Aib, α-Me-Leu) enhancing stability
C20 fatty diacid conjugateextending activity duration in research models
Triple receptor selectivityfor simultaneous GIP, GLP-1, and glucagon agonism
Stable lyophilized formulationoptimized for controlled long-term storage and reconstitution
Consistent analytical verificationvia mass spectrometry, HPLC, and peptide structural mapping

For laboratory research use only. This research-grade material is distinct from pharmaceutical formulations and is intended exclusively for controlled laboratory investigation, not for human or veterinary application.

How is Retatrutide 5mg synthesized?

Retatrutide 5mg is produced using solid-phase peptide synthesis (SPPS), a well-established methodology in which individual amino acids are sequentially coupled to a resin-bound growing chain. This process utilizes Fmoc (9-fluorenylmethoxycarbonyl) protective group chemistry, enabling precise incorporation of the 39-residue sequence, including specialized nonstandard amino acids such as Aib and α-methyl-leucine at their designated positions. Following linear assembly completion, the crude peptide is cleaved from the solid support and undergoes multi-step purification via reversed-phase HPLC to remove incomplete sequences, coupling by-products, and other impurities. Mass spectrometry analysis and HPLC retention-time mapping confirm molecular weight accuracy and structural integrity. The purified peptide is then conjugated to the C20 fatty diacid moiety via linker chemistry at position 17, which enhances its biological activity profile in research systems. The final product is converted to its acetate salt form and lyophilized to produce a stable white to off-white hygroscopic powder. Researchers who buy retatrutide receive material synthesized through this rigorous process, meeting established pharmaceutical quality standards for peptide research applications.

What is Retatrutide 5mg being studied for? What are its possible benefits?

Retatrutide 5mg is being investigated in laboratory and preclinical research models for its multi-pathway metabolic effects. Research has focused on how triple-receptor agonism influences glucose homeostasis, energy expenditure, appetite regulation, and lipid metabolism through simultaneous activation of GIP, GLP-1, and glucagon signaling. These investigations remain exploratory and confined exclusively to laboratory environments and published preclinical research, contributing mechanistic insights into how multi-target peptides interact with metabolic regulatory systems. Potential biological areas under investigation include:

Multi-receptor metabolic signalingthrough simultaneous GIP, GLP-1, and glucagon activation
Energy expenditure modulationacross central and peripheral metabolic circuits
Glucose homeostasisand insulin-dependent metabolic pathways in controlled models
Lipid metabolism and hepatic fat handlingin preclinical research systems
Appetite regulationthrough neural circuit investigation in laboratory animals

These research areas represent ongoing mechanistic investigations with no established therapeutic benefits. Published clinical trial data demonstrate retatrutide's pharmacological mechanisms in pharmaceutical development contexts; however, this research-grade material is studied exclusively for laboratory mechanistic understanding and is not formulated, validated, or intended for clinical application. No therapeutic claims should be inferred from published clinical data when discussing this research-grade peptide.

How does Retatrutide 5mg work in research studies?

In laboratory settings, retatrutide is believed to function as a selective agonist of three distinct G-protein-coupled receptors (GPCRs)—the GIP receptor, GLP-1 receptor, and glucagon receptor—enabling simultaneous activation of multiple metabolic signaling cascades. Upon receptor binding, these activated receptors initiate intracellular cAMP-dependent signaling pathways and downstream protein kinase activation, which researchers use as functional readout markers of receptor engagement and metabolic pathway modulation. Research studies have documented that retatrutide agonism influences multiple intracellular signaling nodes, including adenylyl cyclase activation and cAMP production across receptor-expressing tissues. The peptide's C20 lipid conjugate provides albumin-binding properties that extend its bioavailability duration in research models compared to unmodified peptides. Furthermore, studies have explored how retatrutide's triple-agonist activity modulates neural circuits involved in appetite and energy balance, affects insulin secretion mechanisms, and influences hepatic glucose output and lipid metabolism in controlled preclinical systems. These observations remain limited to laboratory research and animal models, representing theoretical mechanistic investigations rather than clinically validated effects in human biology.

What dosing information exists for Retatrutide 5mg?

Dosing information for research-grade retatrutide derives from published preclinical research and clinical development studies. Important disclaimer: Published clinical trial dosing data (0.5–12 mg weekly in human studies) pertain to pharmaceutical development programs; this research-grade material is for laboratory investigation only and should not be interpreted through a clinical dosing framework. In published preclinical animal research, retatrutide has been studied at various concentrations to establish pharmacokinetic and pharmacodynamic relationships. In vitro cellular research employs retatrutide at nanomolar to micromolar concentrations (typically 0.1–100 nM), depending on the cell type expressing target receptors and the specific metabolic signaling pathway being investigated. Researchers designing laboratory experiments should consult published preclinical protocols and dose-response curves rather than clinical trial data, as research-grade material specifications and pharmaceutical formulations differ fundamentally in composition, purity requirements, and intended use. Notably, all dosing and mechanistic findings should be derived exclusively from published preclinical literature when designing experiments with retatrutide 10 mg vial materials or other research-grade preparations.

How should Retatrutide 5mg be stored and handled?

Retatrutide should be stored at −20 °C in its lyophilized form, protected from light, moisture, and temperature fluctuations. The peptide can be stored up to 24 months. Vials should remain sealed until use and stored in a cool, dry location away from direct light exposure and excessive humidity.

Short-term storage at 2–8 °C (standard refrigerator temperature)is acceptable for limited durations (typically 24–48 hours) if immediate use is planned, though extended storage should occur at −20 °C or lower.
Once reconstituted with bacteriostatic water or appropriate sterile diluent, retatrutide solutions should be refrigerated at 2–8 °Cand not frozen. Reconstituted solutions have limited stability; researchers should prepare fresh solutions for each experiment or maintain reconstituted material for no longer than 7–14 daysunder refrigeration, depending on diluent composition and storage conditions.

Handling Precautions: Avoid repeated freeze-thaw cycles, which degrade peptide structure and compromise integrity and protect from elevated temperatures above 30 °C (86 °F). Minimize light exposure by storing in original vials or amber-colored containers. Researchers should use aseptic, sterile laboratory procedures during all reconstitution and handling. Additionally, gently swirl vials to dissolve lyophilized material; do not shake vigorously to prevent aggregation. Keep all reconstituted solutions clearly labeled with content, concentration, date, and storage conditions. Aliquot reconstituted material into smaller portions to prevent unnecessary thawing. These recommendations align with standard practices for handling retatrutide for research applications and other peptide research materials requiring preservation of molecular integrity.

Where can I read more research about Retatrutide 5mg?

Researchers can explore the following peer-reviewed sources for detailed information about Retatrutide: These publications include molecular research, metabolic studies, and early-phase clinical investigations relevant to the peptide.

Compliance Statement

This product is intended for laboratory research use only and is not approved for human or veterinary use.

Shop with Confidence: Product Authenticity is Guaranteed

All products available at Doctor Medica shop are obtained from respective manufacturers and contain original LOT numbers Contact us if you have any questions about product LOT numbers.

+1-866-343-2413, +1-866-485-6820

info@doctormedica.co